&lt;p&gt;Case Report on Patients with Steinert Disease Complicated by COVID-19&lt;/p&gt;

Chalela, Roberto; Caguana, Oswaldo; Zuccarino, Flavio; Khilzi, Karys; Rodríguez-Chiaradia, Diego A.

doi:10.2147/vhrm.s266659

Cited by 3 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of studies, 16, described syncopal episodes of unexplained etiology (Romero-Sánchez et al, 2020, Pérez et al, 2020, Chachkhiani et al, 2020, Xiong et al, 2020, Radmanesh et al, 2020, Chuang et al, 2021, Pérez et al, 2020Mizrahi et al, 2020, Martín-Sánchez et al, 2020, Travi et al, 2020, Argenziano et al, 2020, Gonfiotti et al, 2020, García-Moncó et al, 2020, Chen et al, 2020, Lam et al, 2020, Chou et al, 2021. 10 case reports alluded to possible cardiac etiology for syncope (Sang et al, 2020, Pasquetto et al, 2020, Luetkens et al, 2020, Chang et al, 2020, Khan et al, 2020, Chalela et al, 2020, Chibane et al, 2020, Pendower et al, 2020, Aoi et al, 2020, Doodnauth et al, 2021 as well as 1 case series (Espinoza et al, 2021), while another 6 studies attributed the cause of syncope to orthostatic hypotension (Ebrille et al, 2020, Tapé et al, 2013, Logmin et al, 2020, Singhania et al, 2020, Huang et al, 2020, Omotosho et al, 2021. In turn, reflex syncope was highlighted in only 3 of the studies (Ebrille et al, 2020, Canetta et al, 2020, Birlutiu et al, 2020.…”

Section: Synthesis Of Resultsmentioning

confidence: 99%

“…However, the elevation of C-reactive protein and D-dimer was more frequently observed than the elevation of troponin. From the studies that discriminated laboratory data on admission, we found that the elevation of D-dimer and C-reactive protein was present in 32% of the patients that presented with COVID-19 and syncope (Sang et al, 2020, Luetkens et al, 2020, Logmin et al, 2020, Khan et al, 2020, Chalela et al, 2020, Pérez et al, 2020, Chibane et al, 2020, Pendower et al, 2020, Aoi et al, 2020, Birlutiu et al, 2020, Espinoza et al, 2021. On the other hand, the elevation of troponin was observed in 23% of these patients (Pasquetto et al, 2020, Luetkens et al, 2020, Birlutiu et al, 2020, Espinoza et al, 2021.…”

Section: Tablementioning

confidence: 89%

“…Of the 37 included articles, 18 were case reports (Tapé et al, 2013, Sang et al, 2020, Pasquetto et al, 2020, Luetkens et al, 2020, Logmin et al, 2020, Chang et al, 2020, Singhania et al, 2020, Huang et al, 2020, Omotosho et al, 2021, Khan et al, 2020, Chalela et al, 2020, Pérez et al, 2020, Chibane et al, 2020, Pendower et al, 2020, Aoi et al, 2020, Doodnauth et al, 2021, Kanjwal et al, 2020, Miglis et al, 2020, 10 were retrospective analyses (Oates et al, 2020, Romero-Sánchez et al, 2020, Chachkhiani et al, 2020, Xiong et al, 2020, Radmanesh et al, 2020, Canetta et al, 2020, Chuang et al, 2021, Mizrahi et al, 2020, Martín-Sánchez et al, 2020, Travi et al, 2020, 5 were case-series (Ebrille et al, 2020, Birlutiu et al, 2020, Argenziano et al, 2020, Espinoza et al, 2021, Gonfiotti et al, 2020 and 2 were prospective studies (García-Moncó et al, 2020, Chen et al, 2020. One was a letter (Lam et al, 2020).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Out of the 18 case reports, syncope was the reason that prompted the visit to the Emergency Department in 13 of them (72.2%) (Tapé et al, 2013, Pasquetto et al, 2020, Luetkens et al, 2020, Logmin et al, 2020, Chang et al, 2020, Singhania et al, 2020, Huang et al, 2020, Chalela et al, 2020, Pérez et al, 2020, Chibane et al, 2020, Pendower et al, 2020, Aoi et al, 2020, Doodnauth et al, 2021. Furthermore, Ebrille et al (2020), Canetta et al (2020) and Espinoza et al (2021) also described syncope as the presenting symptom of the infection.…”

Section: Tablementioning

confidence: 99%

“…Considering confirmed or presumable cardiac syncope, the 13 reported cases included myocarditis (Luetkens et al, 2020), pulmonary embolisms (Khan et al, 2020, Chalela et al, 2020, Chibane et al, 2020, Pendower et al, 2020, Aoi et al, 2020 and ventricular fibrillation (Sang et al, 2020), Brugada Syndrome (Chang et al, 2020, Pasquetto et al, 2020, new onset atrial fibrillation together with anterior wall ST elevation myocardial infarction (Oates et al, 2020), sinus node dysfunction (Doodnauth et al, 2021), non-sustained tachycardia (Espinoza et al, 2021) and sinus bradycardia (Espinoza et al, 2021) as the underlying conditions.…”

Section: Tablementioning

confidence: 99%

See 4 more Smart Citations

Syncope and COVID-19 disease – A systematic review

Freitas

Torres

Martín‐Sánchez

et al. 2021

Autonomic Neuroscience

View full text Add to dashboard Cite

Background: Syncope is not a common manifestation of COVID-19, but it may occur in this context and it can be the presenting symptom in some cases. Different mechanisms may explain the pathophysiology behind COVID-19 related syncope. In this report, we aimed to examine the current frequency and etiology of syncope in COVID-19. Methods: A systematic review across PubMed, ISI Web of Knowledge and SCOPUS was performed, according to PRISMA guidelines, in order to identify all relevant articles regarding both COVID-19 and syncope. Results: We identified 136 publications, of which 99 were excluded. The frequency of syncope and pre-syncope across the selected studies was 4.2% (604/14,437). Unexplained syncope was the most common type (87.9% of the episodes), followed by reflex syncope (7.8% of the cases). Orthostatic hypotension was responsible for 2.2% of the cases and syncope of presumable cardiac cause also accounted for 2.2% of cases. Arterial hypertension was present in 52.0% of syncope patients. The use of angiotensin receptor blockers or angiotensin converting enzyme inhibitors were not associated with an increased incidence of syncope (chi-square test 1.07, p 0.30), unlike the use of beta-blockers (chi-square test 12.48, p < 0.01). Conclusion: Syncope, although not considered a typical symptom of COVID-19, can be associated with it, particularly in early stages. Different causes of syncope were seen in this context. A reevaluation of blood pressure in patients with COVID-19 is suggested, including reassessment of antihypertensive therapy, especially in the case of beta-blockers.

show abstract

Section: Synthesis Of Resultsmentioning

confidence: 99%

Section: Tablementioning

confidence: 89%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Tablementioning

confidence: 99%

Section: Tablementioning

confidence: 99%

See 3 more Smart Citations

Syncope and COVID-19 disease – A systematic review

Freitas

Torres

Martín‐Sánchez

et al. 2021

Autonomic Neuroscience

View full text Add to dashboard Cite

show abstract

COVID-19 and myotonic dystrophy: Case reports and systematic review

Mazzitelli¹,

Trevenzoli²,

Brundu³

et al. 2023

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Steinert's disease is a rare genetic disorder characterized by progressive myotonia and multi-organ damage. It is associated with respiratory and cardiological complications often leading patients to exitus. These conditions are also traditional risk factors for severe COVID-19. SARS-CoV-2 has affected people with chronic diseases, but the impact on people with Steinert's disease is poorly defined, with only a few reported and described. More data are needed to understand whether this genetic disease is a risk factor for more serious evolution or death in patients with COVID-19. Methodology: The study describes two cases of patients with SD and COVID-19 and summarizes available evidence of the clinical outcome of COVID-19 in patients with Steinert's disease, by performing a systematic review of the literature (following PRISMA statements and performing PROSPERO registration). Results: Overall, 5 cases were retrieved from the literature review, with a median age of 47 years, of whom 4 had advanced SD and unfortunately died. By contrast, the 2 patients from our clinical practice and 1 from literature had a good clinical outcomes. Mortality ranged from 57% (all cases) to 80% (only literature review). Conclusions: There is a high mortality rate in patients with both Steinert's disease and COVID-19. It highlights the importance of strengthening prevention strategies, especially vaccination. All SD with SARS-CoV-2 infection/COVID-19 patients should be identified early and treated to avoid complications. It is still unknown which treatment regimen is best to use in those patients. Studies on a greater number of patients are necessary to provide clinicians with further evidence.

show abstract

Syncope and COVID-19

Alranini

Kashour

Al-Hersi

et al. 2022

Journal of Nature and Science of Medicine

View full text Add to dashboard Cite

COVID-19 infection can present with atypical symptoms such as syncope. We reported 2 patients who presented to our emergency department with syncope as a chief complaint. One patient did not have any other symptoms while the other patient developed severe pneumonia later during hospitalization. The cardiac workup including electrocardiogram, cardiac monitoring, and echocardiogram were unremarkable. Both patients were diagnosed with neurally mediated/reflex syncope secondary to COVID-19. No recurrence was reported during follow-up. We then performed a literature review and described previous cases focusing on clinical presentation and the likely mechanism of syncope.

show abstract

<p>Case Report on Patients with Steinert Disease Complicated by COVID-19</p>

Cited by 3 publications

References 11 publications

Syncope and COVID-19 disease – A systematic review

Syncope and COVID-19 disease – A systematic review

COVID-19 and myotonic dystrophy: Case reports and systematic review

Syncope and COVID-19

Contact Info

Product

Resources

About